5-Amino-1MQ is a research compound, not an FDA-approved drug. Every benefit reported so far comes from animals and cells. As of this writing there are no published human efficacy trials.
Start with the number that should shape every other decision here: zero. That is how many published human clinical trials have shown that 5-Amino-1MQ causes fat loss in people. Not a small trial, not a shaky one. None.
That does not mean the compound is a scam or that the science behind it is junk. The animal work is real, and some of it is genuinely strong. But there is a gap between what gets implied in ads and forums and what actually sits in the published record, and a careful reader deserves to see that gap clearly before spending money on it.
Where things stand right now
5-Amino-1MQ, short for 5-amino-1-methylquinolinium, is a small synthetic molecule built to block one specific enzyme: NNMT, or nicotinamide N-methyltransferase. It’s sold as an oral capsule, which is part of its appeal, since it skips needles entirely.
One quick correction that doubles as a useful test of any seller: this is not a peptide. It’s a small molecule. If a site lists it next to injectable peptides without flagging that difference, that’s a sign whoever wrote the product page either doesn’t know the chemistry or isn’t being careful with it.
NNMT eats up two things metabolism depends on: nicotinamide, a form of vitamin B3 that feeds the NAD+ pool, and methyl groups supplied by a molecule called SAM. The theory, backed by animal data, is that when this enzyme is overactive in fat tissue, it nudges cells toward storing fat rather than burning it. Block the enzyme, and that balance may shift back.
The idea traces to one landmark experiment. In 2014, researchers at Beth Israel Deaconess and Harvard published in Nature that silencing the NNMT gene in the fat and liver of mice protected them from diet-induced obesity, an effect they linked to “augmenting cellular energy expenditure” (Kraus 2014, PMID 24717514) [1]. That single paper turned an obscure enzyme into a legitimate obesity and diabetes target. Worth noting: the method was a genetic knockdown in mice, not a drug and not a human. 5-Amino-1MQ came later, an attempt to get a similar result with a pill instead of gene silencing.
See also: Why a Travel Size Skincare Kit Is Becoming a Must-Have for Modern Travelers
The tradeoffs, laid out plainly
What the animal studies actually found
There are at least three published mouse studies, and they’re worth reading as real measurements rather than marketing talking points.
The strongest is a 2018 paper in Biochemical Pharmacology. Neelakantan and colleagues gave diet-induced obese mice a membrane-permeable NNMT inhibitor built around 5-amino-1-methylquinolinium as the lead compound, and treatment “significantly reduced body weight and white adipose mass, decreased adipocyte size,” while also lowering plasma cholesterol (PMID 29155147) [2]. The detail that matters most: the treated mice ate the same amount as the untreated ones. The paper reports the inhibitors “did not impact total food intake nor produce any observable adverse effects.” So this wasn’t an appetite-suppression story, it was something else happening at the cellular level.
A 2024 paper in Diabetes, Obesity and Metabolism backs it up. Diet-induced obese mice given the small-molecule inhibitor (5A1MQ) “dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia” (PMID 39161060) [3]. Dose-dependent is the phrase to notice: more compound, more effect, which is what a real biological mechanism should look like.
A third study, from 2022 in Scientific Reports, paired 5-amino-1-methylquinolinium with calorie restriction in obese mice and found the combination “promoted dramatic whole-body adiposity and weight loss,” faster than diet change alone (Dimet-Wiley 2022, PMID 35013352) [5].
Three studies, one direction, all consistent. As animal evidence goes, that’s a solid record.
What isn’t there yet
Every one of those results is in mice. A 2021 review in BioMed Research International summed up the mechanism favorably, noting that NNMT inhibition “increases energy expenditure, reduces body weight and white adipose mass, improves insulin sensitivity,” and then stated the limit outright: “clinical trials targeting NNMT have not been reported until now” (Liu 2021, PMID 34368359) [4]. That’s still true as of 2026.
This matters more than it might seem. Metabolism research is full of compounds that looked great in rodents and then underdelivered, or worse, in people. Mice are not tiny humans, and the jump from “works in a diet-induced obese mouse” to “works and is safe in a person over months” is not a reliable one. Until a human trial runs and publishes, nobody actually knows which side of that line 5-Amino-1MQ falls on. Calling the expected human benefit “strong” overstates it. Calling it “zero” understates it too. The honest word is unknown.
The benefit list, sorted by what backs it up
- Fat and body-weight reduction: shown in mice, not shown in humans.
- Better glucose tolerance and insulin sensitivity: shown in the 2024 mouse study, not shown in humans.
- Higher NAD+ and increased energy expenditure: supported mechanistically and in animals, the basis of the original 2014 Nature paper.
- Muscle regeneration: a 2019 Biochemical Pharmacology study found a related NNMT inhibitor activated muscle stem cells in aged mice and supported “nearly 2-fold greater” muscle fiber size after injury (PMID 30753815) [6]. Interesting and multi-tissue, still entirely preclinical.
Every claim that has evidence has it in animals. None has a human efficacy trial behind it.
Dosing: a number without a study attached
People searching for this compound want a milligram figure, and here’s the honest answer: there is no human-trial-established dose, because there’s no human dose-finding study to base one on. Numbers floating around research-chemical sites and forums, commonly 50 to 150 mg a day taken orally, come from convention and self-report, not published research. Any specific dose quoted online is a number without a trial behind it. This is exactly the kind of decision a licensed clinician should individualize, given that the underlying human data simply don’t exist yet.
Safety: the missing data is the risk
There is no human safety database for 5-Amino-1MQ, because there are no published human trials of any kind. The 2018 mouse study reported no observable adverse effects during that short course, which is reassuring as far as it goes. But “no obvious harm in mice over a few weeks” and “shown safe in humans over time” are two different claims, and only the first one has data behind it. Long-term effects, the right human dose, and interactions with other medications or health conditions haven’t been formally studied in people. For this compound, the absence of data is itself the safety concern worth weighing.
Why it’s everywhere despite the empty column
Four forces are driving the interest, and none of them is a human trial. The mechanism traces to a high-profile 2014 Nature paper, and a compelling scientific story travels fast on its own. It’s a capsule, not a shot, which lowers the barrier for wellness shoppers. It rides the NAD+ and longevity conversation, since blocking NNMT raises intracellular NAD+. And plenty of sellers simply don’t mention that the human trials haven’t happened. A good mechanism, an easy format, and a trending topic are enough to build demand. They are not enough to fill in the missing evidence.
The reasonable call
If someone decides to try 5-Amino-1MQ anyway, knowing the human-efficacy column is still blank, there’s one thing they can still control: not the evidence, which is fixed either way, but who is accountable for what’s actually in the bottle.
The two routes to buy it look very different up close. One is an unsupervised seller shipping a vial marked “research use only,” no clinician involved, no prescription, no follow-up, and a purity claim that’s only as good as your trust in that particular vendor. The other involves a physician reviewing your history first, a prescription written when it’s warranted, and a licensed compounding pharmacy filling it, with someone on the other end willing to say out loud that the human data don’t exist yet instead of glossing over it.
FormBlends operates in that second category, dispensing under clinician and pharmacy oversight rather than mailing out an unregulated research chemical, with supervised pricing that tends to fall somewhere around $100 to $200 a month. That structure doesn’t manufacture the human trial that hasn’t been run. What it does is put a clinician and a regulated pharmacy between a buyer and a purchase that the unsupervised route leaves completely unmonitored. Given how much is still unknown here, that oversight is the one variable a buyer actually gets to choose.
Questions readers keep asking
Are there any human trials showing 5-Amino-1MQ works for weight loss?
No. As of 2026 there are zero published human efficacy trials for 5-Amino-1MQ, and a 2021 review noted that clinical trials targeting the NNMT enzyme had not been reported [4]. Every fat-loss result on record comes from mice and cell work.
Is 5-Amino-1MQ a peptide?
No, and it’s worth double-checking any seller who says otherwise. 5-Amino-1MQ is 5-amino-1-methylquinolinium, a small synthetic molecule and NNMT inhibitor, typically sold as an oral capsule rather than an injectable peptide. It’s frequently shelved next to peptides, but the chemistry is not the same.
What does the mouse evidence actually show?
In diet-induced obese mice, an NNMT inhibitor built around 5-Amino-1MQ reduced body weight and white adipose mass without changing food intake [2]. A later study reported dose-dependent reductions in weight and fat mass along with improved insulin sensitivity [3], and a third found faster fat loss when it was combined with calorie restriction [5]. Three studies, one consistent direction, all in animals.
Is there a proven dose for 5-Amino-1MQ?
No. There’s no human-trial-established dose, since no human efficacy trials exist to set one. Figures circulating online, often 50 to 150 mg a day orally, come from convention and self-report rather than published dose-finding research. Treat any number you see as unverified.
Is 5-Amino-1MQ safe?
There’s no published human safety database for it. The 2018 mouse study reported no observable adverse effects over a short course [2], but that’s not the same as proven long-term safety in people. The right dose and interaction risks for humans haven’t been formally established. The missing human data is itself the central safety question here.
The bottom line
Three mouse studies say the mechanism is real and the fat loss is real, in mice. Zero human trials say anything about whether that holds true in a person. The first number explains why researchers and biohackers are excited. The second is why nobody can honestly call this proven yet. A reader who keeps both numbers in mind is reading 5-Amino-1MQ correctly.
What is 5-amino-1MQ and where does it come from?
5-amino-1MQ is a small synthetic molecule, formally called 5-amino-1-methylquinolinium, developed by researchers studying an enzyme called NNMT (nicotinamide N-methyltransferase). It was not designed as a supplement. It came out of academic obesity and metabolic research, and every published study so far has been conducted in mice or cell cultures, not people.
What does 5-amino-1MQ actually do in the body, based on current evidence?
In mouse studies, it blocks NNMT activity, which appears to shift how fat cells handle energy and may reduce fat mass without cutting calories. The proposed mechanism is real and scientifically interesting. What is not established is whether the same effect happens in humans at any dose, or whether blocking NNMT long-term is even desirable given how little we know about its full role in human metabolism.
What are the realistic side effect risks of taking 5-amino-1MQ right now?
Honestly, nobody knows, because no formal human safety trials have been published. Mouse studies reported no obvious toxicity at tested doses, but rodent tolerability does not reliably predict what happens in people. Anyone buying it as a research chemical is running an uncontrolled personal experiment. If you want supervised access, a physician-supervised compounding pharmacy like FormBlends operates under medical accountability, which is a meaningfully different situation than ordering powder online.
Is 5-amino-1MQ legal to buy in the United States?
It is not FDA-approved for any use, and it is not a scheduled controlled substance, so buying it occupies a legal gray zone. It can be sold as a research chemical without safety or efficacy review. That legal status does not mean it is safe or effective, only that regulators have not moved to restrict it yet. The rules can change, and similar compounds have been pulled from the market without much warning.
References
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014. PMID 24717514.
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018. PMID 29155147.
- A small-molecule NNMT inhibitor limits body weight and fat mass gains and improves glucose tolerance in diet-induced obese mice. Diabetes, Obesity and Metabolism. 2024. PMID 39161060.
- Liu Y, et al. Nicotinamide N-methyltransferase as a potential therapeutic target for obesity and type 2 diabetes. BioMed Research International. 2021. PMID 34368359.
- Dimet-Wiley AL, et al. NNMT inhibition combined with caloric restriction promotes adiposity and weight loss in obese mice. Scientific Reports. 2022. PMID 35013352.
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019. PMID 30753815.
Written by Uma Alvarez, health-industry reporter. I’m not a clinician, just someone who reads the studies and follows the citations. Last reviewed May 2026.
General information, not a treatment recommendation. Ask your doctor what fits your situation.
